摘要
溶血性尿毒症综合征是一少见而凶险疾病，随着对该病病因和发病机制认识的逐步提高，治疗上除了目前广泛采用的血浆置换，近年来的热点还关注于靶目标的治疗如研制防止志贺菌毒素攻击靶器官的新制剂、志贺菌毒素中和抗体、疫苗、补体抑制刺等，以及有争议的抗生素、肾移植的应用。本文就溶血性尿毒症综合征治疗新进展研究中的关键与热点问题作一综述。
出处
《国际泌尿系统杂志》
2008年第4期546-550,共5页
International Journal of Urology and Nephrology
参考文献25
-
1Seto EY, Soller JA, Colford JM Jr. Strategies to reduce person - to - person transmission during widespread Escherichia coli O157 :H7 outbreak. Emerg Infect Dis,2007,13 ( 6 ) : 860 - 866. 被引量：1
-
2Noris M, Remuzzi G, Hemolytic Uremic Syndrome. J Am Soc Nephrol, 2005,16(5 ) : 1035 - 1050. 被引量：1
-
3MacConnachie AA, Todd WT. Potential therapeutic agents for the prevention and treatment of haemolytic uraemic syndrome in shiga toxin producing Escherichia coli infection. Curr Opin Infect Dis ,2004 ,17(5) :479 -482. 被引量：1
-
4Trachtman H,Cnaan A, Christen E ,et al. Effect of an oral Shiga toxin -binding agent on diarrhea- associated hemolytic uremic syndrome in children : a randomized controlled trial. JAMA, 2003, 290 ( 10 ) :1337 - 1344. 被引量：1
-
5Pinyon RA,Paton JC, Paton AW, et al. Refinement of a therapeutic Shiga toxin - binding probiotic for human trials. J Infect Dis, 2004, 189(9) :1547 - 1555. 被引量：1
-
6Neri P, Nagano SI, Yokoyama S, et al. Neutralizing activity of polyvalent Gb3, Gb2 and galacto - trehalose models against Shiga toxins. Microbiol Immunol,2007,51 (6) :581 - 592. 被引量：1
-
7Kuribayashi T, Seita T, Fukuyama M, et al. Neutralizing activity of bovine colostral antibody against verotoxin derived from enterohemorrhagic Escherichia coli O157 :H7 in mice. J Infect Chemother,2006, 12 (5) :251 - 256. 被引量：1
-
8Wen SX, Teel LD, Judge NA, et al. A plant - based oral vaccine to protect against systemic intoxication by Shiga toxin type 2. Proc Natl Acad Sci U S A,2006, 103(18) :7082 -7087. 被引量：1
-
9Ahmed A, Li J, Shiloach Y, et al. Safety and immunogenicity of Escherichia coli 0157 O - specific polysaccharide conjugate vaccine in 2 -5 -year - old children. J Infect Dis,2006, 193(4) : 515 - 521. 被引量：1
-
10Bennish ML, Khan WA, Begum M, et al. Low risk of hemolyt uremic syndrome after early effective antimicrobial therapy fo Shigella dysenteriae type 1 infection in Bangladesh. Clin Infect Dis, 2006, 42(3) : 356 -362. 被引量：1
二级参考文献18
-
1Bennish ML,Khan WA,Begum M,et al.Low risk of hemolytic uremic syndrome after early effective antimicrobial therapy for Shigella dysenteriae type 1 infection in Bangladesh[J].Clin Infect Dis,2006,42(3):356-362. 被引量：1
-
2Ikeda K,Ida O,Kimoto K,et al.Effect of early fosfomycin treatment on prevention of hemolytic uremic syndrome accompanying Escherichia coli O157:H7 infection[J].Clin Nephrol,1999,52(6):357-362. 被引量：1
-
3Shiomi M,Togawa M,Fujita K,et al.Effect of early oral fluoroquinolones in hemorrhagic colitis due to Escherichia coli O157:H7[J].Pediatr Int,1999,41(2):228-232. 被引量：1
-
4Higami S,Nishimoto K,Kawamura T,et al.Retrospective analysis of the relationship between HUS incidence and antibiotics among patients with Escherichia coli O157 enterocolitis in the Sakai outbreak[J].Kansenshogaku Zasshi,1998,72(3):266-272. 被引量：1
-
5Isogai E,Isogai H,Hayashi,et al.Effect of antibiotics,LVFX and FOM,on a mouse model with Escherichia coli O157 infection[J].Microbiol Immunol,2000,44(1):89. 被引量：1
-
6Ohara T,Kojio S,Taneike I,et al.Effects of azithromycin on shiga toxin production by Escherichia coli and subsequent host inflammatory response[J].Antimicrob Agents Chemother,2002,46(11):3478-3483. 被引量：1
-
7Basualdo W,Arbo A.Randomized comparison of azithromycin versus cefixime for treatment of shigellosis in children[J].Pediatr Infect Dis J,2003,22(4),374-377. 被引量：1
-
8Kurioka T,Yunou Y,Harada H,et al.Efficacy of antibiotic therapy for infection with Shiga-like toxin-producing Escherichia coli O157:H7 in mice with protein-calorie malnutrition[J].Eur J Clin Microbiol Infect Dis,1999,18(8):561-571. 被引量：1
-
9Wong CS,Jelacic S,Habeeb RL,et al.The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections[J].N Engl J Med,2000,342(26):1930-1936. 被引量：1
-
10Zimmerhackl LB.E.coli,antibiotics,and the hemolytic-uremic syndrome[J].N Engl J Med,2000,342(26):1990-1991. 被引量：1
同被引文献5
-
1张颖,周新,李霞.补体因子H与非典型性溶血性尿毒综合征[J].国外医学（临床生物化学与检验学分册）,2004,25(4):336-338. 被引量：1
-
2唐向国,叶礼燕,余自华,任榕娜,陈光明,王承峰,夏桂枝,黄隽,黄俊景,聂晓晶.溶血尿毒综合征患儿MCP基因突变分析[J].临床儿科杂志,2008,26(12):1045-1048. 被引量：2
-
3孔秀岩,苏志刚.溶血性尿毒症综合征的肾损害[J].河北医药,2009,31(4):473-475. 被引量：6
-
4杨柳,谢红浪.非典型溶血尿毒综合征[J].肾脏病与透析肾移植杂志,2016,25(1):72-76. 被引量：4
-
5Maurizio Salvadori,Elisabetta Bertoni.Update on hemolytic uremic syndrome:Diagnostic and therapeutic recommendations[J].World Journal of Nephrology,2013,2(3):56-76. 被引量：13
-
1李萍,肖平,范磊.非典型鲍氏Ⅴ型志贺菌致泌尿系感染[J].上海医学检验杂志,1998,13(3):152-152.
-
2牛效清,宫磊,张浩,刘中柱.促红细胞生成素干预肾性贫血治疗靶目标的临床观察[J].黑龙江医药科学,2014,37(2):8-9. 被引量：1
-
3慢性肾脏病骨代谢及其疾病的临床实践指南——指南7 对慢性肾脏病患者维生素D缺乏与不足预防的治疗[J].中国血液净化,2006,5(4):225-227. 被引量：3
-
4魏林节,冯华,陈志,唐卫华,杨云峰,缪洪平,牛胤,李兰,朱刚.草麻黄中补体抑制单体防治大鼠脑冲击伤的研究[J].第三军医大学学报,2012,34(23):2360-2363.
-
5蒲蕾,王莉.肾性贫血治疗靶目标的再认识[J].中国血液净化,2012,11(9):465-467. 被引量：2
-
6马乾年,叶剑华,周志阳.一起小学细菌性痢疾暴发的流行病学与临床特征分析[J].中华临床感染病杂志,2012,5(1):44-45. 被引量：3
-
7范瑛,汪年松.慢性肾功能不全患者降压药物的选择[J].世界临床药物,2010,31(3):148-152. 被引量：10
-
8刘慧荣,邵谭,梁峰,郑振群,乔常欣.人精浆的补体抑制活性与抗精子免疫不育的关系[J].中国计划生育学杂志,1998,6(6):258-260. 被引量：2
-
9牛效清,张浩,刘艳姝,刘中柱,赵春艳,蔡天蕊.补气养血汤对肾性贫血治疗的时机及靶目标的干预作用[J].黑龙江医药科学,2016,39(2):25-26. 被引量：2
-
10李敏,张程,张湘燕.抑制补体对内毒素致急性肺损伤的保护作用[J].重庆医学,2010,39(16):2095-2097. 被引量：3
